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The SPRTN metalloprotease is essential for DNA-protein crosslink (DPC) repair and DNA
replication in vertebrate cells. Cells deficient in SPRTN protease exhibit DPC-induced repli-
cation stress and genome instability, manifesting as premature ageing and liver cancer. Here,
we provide a body of evidence suggesting that SPRTN activates the ATR-CHK1 phosphor-
ylation signalling cascade during physiological DNA replication by proteolysis-dependent
eviction of CHK1 from replicative chromatin. During this process, SPRTN proteolyses the C-
terminal/inhibitory part of CHK1, liberating N-terminal CHK1 kinase active fragments.
Simultaneously, CHK1 full length and its N-terminal fragments phosphorylate SPRTN at the
C-terminal regulatory domain, which stimulates SPRTN recruitment to chromatin to promote
unperturbed DNA replication fork progression and DPC repair. Our data suggest that a
SPRTN-CHK1 cross-activation loop plays a part in DNA replication and protection from DNA
replication stress. Finally, our results with purified components of this pathway further
support the proposed model of a SPRTN-CHK1 cross-activation loop.
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The timely completion of DNA replication is essential forgenome integrity and preventing the onset of cancer,premature ageing and developmental disorders1,2. DNA
replication is constantly threatened by many factors, including
DNA lesions, collisions with the transcription machinery and
repetitive DNA sequences. Cells have evolved robust DNA
damage tolerance and DNA damage response pathways to cope
with the different lesions and obstacles that challenge the pro-
gression of DNA replication forks3–6. In particular, the ataxia
telangiectasia and Rad3 related (ATR)-CHK1 signalling cascade is
the major regulator of the response to replication stress7,8. This
cascade performs multiple functions in response to DNA repli-
cation stress, including regulating DNA replication origin firing,
stabilising stalled replication forks and delaying mitotic entry by
preventing cyclin-dependent kinase (CDK) 1 and 2 hyper-
activation5,9.
The main stimulus for ATR-CHK1 activation is replication
protein A (RPA)-coated single-stranded (ss) DNA that typically
forms upon DNA replication fork stalling due to uncoupling of
the cell division cycle 45 (Cdc45), minichromosome maintenance
protein complex 2-7 (Mcm2-7) and go-ichi-ni-san protein com-
plex GINS (CMG) helicase complex from DNA polymerases5.
This ssDNA-protein structure recruits the ATR–ATR-interacting
protein (ATRIP) kinase complex which, with the help of Ewing’s
tumour-associated antigen 1 (ETAA1) and DNA topoisomerase
2-binding protein 1 (TopBP1), activates CHK1 by phosphor-
ylating serines 317 and 345 to expose the catalytic N-terminal
domain of CHK110,11. Upon phosphorylation, CHK1 is released
from chromatin by an as yet unknown mechanism and spread
throughout the nucleus and cytoplasm to regulate the activity of
its substrates and safeguard genome stability9,12,13. The ATR-
CHK1 signalling pathway can also be activated in S-phase by
ssDNA generated after 5′-3′ end resection of double strand DNA
breaks (DSB)14.
However, given that ATR-CHK1 kinase activity is required for
physiological DNA replication fork progression—when long
stretches of ssDNA are scarce and the robust activation of ATR-
CHK1 signalling cascade would be deleterious for cells—the
question of how ATR-CHK1 is activated during steady-state
DNA synthesis remains unanswered15–19. Identifying the
mechanisms that regulate ATR-CHK1 signalling under physio-
logical conditions is therefore essential to understand how cells
survive and preserve genomic stability20. Recent work identified
ETAA1 as an activator of ATR during steady-state DNA
replication11,21–24. However, this finding does not explain yet
how CHK1, as a main signalling component downstream of ATR,
is released from chromatin to activate the ATR-CHK1-CDC25-
CDK1/2 signalling cascade.
We and others have recently identified the SPRTN metallo-
protease as being a constitutive component of the DNA replica-
tion machinery and necessary for DNA replication25–30. The
essential role of SPRTN in safeguarding genome stability is
demonstrated both in human disease and in animal models.
Monogenic, biallelic SPRTN germline mutations cause
Ruijs–Aalfs Syndrome (RJALS), a rare disease characterised by
genomic instability, premature ageing and hepatocellular
carcinoma25,31,32. Furthermore, SPRTN hypomorphic mice
develop RJALS-like phenotypes, while complete SPRTN knockout
is embryonic lethal33. SPRTN has recently been identified as an
essential core fitness gene in humans34–36. Finally, down-
regulation of SPRTN in zebrafish severely impairs normal
embryonic development and increases embryonic lethality31.
The source of genome instability in RJALS patient derived cells
and in SPRTN-deficient human and mouse cells was recently
demonstrated to arise from replication stress caused by the
accumulation of replication-blocking DNA-protein crosslinks
(DPC)25,27,28. DPCs are formed by various aldehydes including
formaldehyde (FA), formed as metabolic by-products of lipid
peroxidation and histone and DNA demethylation37–39. As
SPRTN protease activity is required to cleave DPCs, defective
SPRTN protease activity results in profound replication stress,
visualised as increased fork stalling and significantly reduced
DNA replication fork velocity. Strikingly, we observed a severe
G2/M-checkpoint defect in SPRTN-deficient cells treated with
genotoxic agents that interfere with DNA replication31. The G2/
M checkpoint was, however, completely functional after the
induction of non-replication-associated DNA strand breaks using
ionising radiation, suggesting that SPRTN-defective cells lack the
ability to activate CHK1 in response to replication stress when
replication forks are still intact31.
Our results here suggest that SPRTN protease stimulates CHK1
kinase function during physiological DNA replication and vice
versa. Specifically, SPRTN cleaves, evicts and activates CHK1
from replicative chromatin, enabling physiological CHK1 func-
tion during steady-state DNA replication. Our data suggests that
SPRTN proteolysis can cleave the regulatory/inhibitory C-
terminal domain of CHK1 in vitro and in vivo, and the
released N-terminal CHK1 products are kinase active. These N-
terminal CHK1 products, when ectopically expressed, are suffi-
cient to stabilise DNA replication forks in a CHK1 kinase-
dependent but ATR-independent manner. The N-terminal CHK1
fragments also rescue embryonic development defect and genome
instability in cells where SPRTN is depleted to approximately 30%
of wildtype cells. This rescue is dependent of CHK1 phosphor-
ylating the C-terminus of the residual SPRTN, further promoting
SPRTN recruitment to chromatin for the removal of DPCs in
front of unperturbed DNA replication fork progression. Finally,
activation of CHK1 by SPRTN proteolysis in vitro further sup-
ports our proposed model of a SPRTN-CHK1 cross-
activation loop.
Results
SPRTN deficiency leads to aberrant ATR-CHK1 signalling
cascade. Analysis of RJALS patient and SPRTN-depleted cells
revealed that SPRTN protease activity is essential for DNA
replication fork progression, cell cycle progression and G2/M
checkpoint activation after DNA replication stress but not
ionising radiation25,28,31. These results suggest that SPRTN
bridges DNA replication and G2/M-checkpoint regulation. To re-
evaluate these findings, we performed analysis of DNA replication
using the DNA fiber assay (Fig. 1a). Depletion of SPRTN by three
independent siRNA sequences caused severe DNA replication
stress in human embryonic kidney 293 (HEK293) cells, visualised
as a reduction in DNA replication fork velocity and an increased
frequency of fork stalling (Fig. 1b–d). Short treatment of control
cells with a low dose of hydroxyurea (HU), a drug that limits the
cellular dNTP pool, was used as a positive control of DNA
replication stress phenotypes. In general, as a response to DNA
replication stress, cells suppress dormant origin firing, as was
visible after HU treatment (Fig. 1e). Interestingly, dormant origin
firing was more than 3-fold higher in SPRTN-depleted cells when
compared to HU-treated cells. As firing of dormant origins is
tightly regulated by the CHK1 kinase40,41, which also controls the
G2/M-checkpoint42,43, we asked whether the ATR-CHK1 sig-
nalling was defective in SPRTN-inactivated cells. ATR-CHK1
signalling, visualised by CHK1 S345 phosphorylation, was not
activated in SPRTN-depleted cells (Fig. 1f, g) despite these cells
showing the classical signatures of DNA replication stress
visualised by the DNA fibers (Fig. 1b–e). Accordingly, CHK1
kinase activity was not activated as demonstrated by the lack of
CHK1 phosphorylation on serine 296 (S296), the residue that
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CHK1 auto-phosphorylates once its kinase activity has been sti-
mulated by ATR44,45. Furthermore, despite being in similar cell
cycle stages (Supplementary Fig. 1a–c), SPRTN-depleted cells
exhibited less CHK1-S296 and -S345 phosphorylation than even
unchallenged control cells and ∼9–10-fold less than HU-treated
control cells, which showed similarly reduced replication fork
velocity and elevated levels of fork stalling as SPRTN-depleted
cells (Fig. 1f, g). Similar findings were observed in HeLa cells (see
below). These results show that SPRTN-inactivated human cells
fail to activate a robust ATR-CHK1 response despite exhibiting
severe replication stress phenotypes that would ordinarily be
expected to elicit such a response, namely CHK1 chromatin
eviction and consequent activation of CHK1 signalling12.
Indeed, SPRTN-inactivated cells accumulate over 2-fold more
CHK1 on chromatin when compared to unchallenged control
cells, a similar effect as in cells treated with the DNA-protein
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crosslinking agent formaldehyde (FA), but opposite to cells
treated with HU, where CHK1 is released from chromatin
(Supplementary Fig. 1d, e).
To further validate this observation, we treated HEK293 cells
with UCN-01, a well-characterised CHK1 inhibitor16,46,47. UCN-
01 treatment in control cells caused a severe reduction in
replication fork velocity and increased the frequency of new
(dormant) origin firing and fork stalling (Fig. 1h–j). UCN-01,
however, had no additive effect on replication fork velocity, new
origin firing, or fork stalling in SPRTN-depleted cells. In addition,
in comparison to wt cells, SPRTN-haploinsufficient HeLa
(ΔSPRTN) cells were relatively much less sensitive to UCN-01
treatment (Fig. 1k). This further suggests that CHK1 is not fully
activated in SPRTN-defective human cells. Altogether, these
results highlight the importance of CHK1 activity during steady-
state DNA replication15,16,19, demonstrate an epistatic relation-
ship between SPRTN and CHK1, and reveal a severe defect in
CHK1 kinase activation in SPRTN-defective cells despite them
suffering from severe DNA replication stress. We concluded that
SPRTN-defective cells lack the optimal (physiological) ATR-
CHK1 activity required for DNA replication and genome
stability, due to their inefficiency in evicting CHK1 from
chromatin, and thus activating a steady-state CHK1 signalling
cascade.
SPRTN regulates CHK1 activity under physiological condi-
tions. To test this conclusion, we investigated the signalling
pathway downstream of ATR-CHK1 by monitoring the total
levels of the CHK1 target, protein phosphatase Cdc25A3. Upon
phosphorylation by CHK1, Cdc25A is degraded by the protea-
some, as observed in cells treated with HU (Fig. 1f and Supple-
mentary Fig. 1f). Consequently, CDK1/2 are hyper-
phosphorylated and become inactive, which leads to intra S-
phase and G2/M-checkpoint activation and cell cycle arrest48,49.
CDK1 and 2 drive S-phase progression and the G2/M cell cycle
transition, but hyper-activation of CDK1/2 negatively influences
DNA replication fork stability and causes premature mitotic
entry50,51. Hence, the ATR-CHK1-Cdc25-CDK1/2 pathway is
necessary to regulate cell cycle progression during DNA synthesis.
Due to faulty CHK1 activation, SPRTN-depleted cells hyper-
accumulated Cdc25A (Fig. 1f and Supplementary Fig. 1f), which
in turn dephosphorylates and hyper-activates CDK1/2, as was
visible by the increased phosphorylation of total CDK1/2 sub-
strates in HEK293 cell extracts (Supplementary Fig. 1g, h).
CHK1 overexpression corrects SPRTN-defective phenotypes.
To assess whether the failure to activate ATR-CHK1 signalling
could explain the DNA replication phenotypes and G2/M defects
observed in SPRTN-depleted cells (Fig. 1)31, we ectopically
expressed CHK1-wild type (wt) or its ATR-dependent phos-
phorylation (phospho)-defective variants (CHK1-S317A or
CHK1-S345A) (Fig. 2a, b and Supplementary Fig. 2a). CHK1-wt,
but not CHK1-S317A or CHK1-S345A, restored DNA replication
fork velocity, suppressed new origin firing and rescued replication
fork stalling in SPRTN-depleted cells. Moreover, ectopic expres-
sion of CHK1-wt in SPRTN-deficient cells also corrected chro-
mosomal instability, measured by the number of chromosomal
aberrations on mitotic chromosomes (Fig. 2c and Supplementary
Fig. 2b). These results further support our initial observation that
SPRTN-inactivation leads to an impaired ATR-CHK1 signalling
cascade, resulting in severe DNA replication stress, a defective
G2/M checkpoint and the accumulation of chromosomal aber-
rations in SPRTN-deficient cells31,33. These results also suggest
that the ATR kinase is required for the full CHK1 activation
in vivo as the CHK1 variants, S317A and S345A (ATR-phos-
phorylation sites), are dominant negative even in wild type cells
(Fig. 2a, b) where SPRTN function is intact. These results are in
consonance with previously published literature on CHK144,52.
The SPRTN-ATR-CHK1 axis is essential in zebrafish embryos.
To investigate and validate our observations so far on an orga-
nismal level, we took advantage of the zebrafish model system.
We have previously shown that morpholino (MO)-mediated
depletion of SPRTN in zebrafish embryos causes severe devel-
opment defects and accumulation of DNA damage31. When
fertilized eggs with SPRTN MO were co-injected with capped
RNAs encoding for GFP-CHK1-wt, both developmental retar-
dation and DNA damage (the latter analysed by γH2AX accu-
mulation) were rescued (Fig. 2d–h and Supplementary Fig. 2c).
Conversely, reconstitution with RNAs encoding ATR-dependent
phospho-defective variants of GFP-CHK1, S317A or S345A,
failed to rescue the phenotypes of SPRTN depletion in early
zebrafish embryos. Altogether, these data suggest that the
restoration of CHK1 activity is able to compensate for SPRTN-
deficiency in human cells and zebrafish embryos, and that the
SPRTN-CHK1 axis is conserved in vertebrates and dependent on
ATR activity.
SPRTN does not contribute to CHK1 activation after DNA
breaks. Interestingly, when SPRTN-depleted cells were chal-
lenged with HU, CHK1 was activated to the same extent as in
HU-treated control cells (Fig. 3a, lanes 2, 4, 6 and 8). This CHK1
activation was concomitant with phosphorylation of ATM, CHK2
and RPA, indicating DSB formation42,53. Moreover, the total level
of RPA remained unchanged in these cells and phosphorylation
of RPA ruled out the possibility that severe replication stress in
Fig. 1 SPRTN depleted cells endure severe DNA replication stress but fail to activate a CHK1 response. a Schematic representation of DNA fiber assay. See
also Methods. b DNA fibers obtained from HEK293 cells that have been treated with the indicated siRNAs against SPRTN (siSPRTN) or with hydroxyurea
(HU). Scale bar: 10 µm. Data shown are representative images of three independent experiments. c–e DNA fiber assay analysis showing replication fork
length (c), stalled replication forks (d) and newly fired origins (e). c siSPRTN cells exhibit decreased fork velocity. >100 individual IdU tracts were measured
per experiment per condition. Data are shown as mean with 25–75% percentile range (box) and 10–90% percentile (whiskers); n= 3 independent
experiments, two-tailed Student's t-test. d siSPRTN cells exhibit an increased frequency of stalled replication forks. >400 forks were scored per condition
per experiment. Mean ± SEM; n= 3 independent experiments, two-tailed Student's t-test. e siSPRTN cells exhibit increased newly firing of dormant origin,
contrary to cells treated with HU. >400 forks were scored per condition per experiment. Mean ± SEM; n= 3 independent experiments, two-tailed Student's
t-test. f Knock-down of SPRTN in HEK293 cells diminishes the phosphorylation status of CHK1 residues S296 and S345, and enhances Cdc25A stability,
contrary to treatment with HU. Immunoblots were run with whole cell lysates and represent three independent experiments. g Quantifications for (f) of
CHK1 phosphorylation signal at residues S345 and S296, normalised to vinculin. Mean ± SEM; n= 3 independent experiments, two-tailed Student's t-test.
h–j Treatment of cells with the CHK1 inhibitor UCN-01 induces severe replication stress to a similar extent as SPRTN-inactivation, detected by DNA fiber
assay analysis. Schematic representation of experimental layout showing the addition of UCN-01 with IdU is also shown in (h, top); d: day. k Cell growth of
wt and SPRTN-deficient (ΔSPRTN) HeLa cells in response to the CHK1 inhibitor UCN-01 (300 nM) on day 4 after seeding cells at same density (day 0).
Mean ± SEM; n= 3 independent experiments, two-tailed Student's t-test. Source data for (c–k) are provided as a Source Data file
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SPRTN-inactivated cells results from RPA exhaustion54. Similar
findings were observed in haploinsufficient HeLa SPRTN cells (Δ-
SPRTN) (Fig. 3b, c). Taken together, our data suggest that
SPRTN-deficient human cells have a fully functional ATR-CHK1
signalling pathway in the context of DSB repair, but that SPRTN
is needed to activate this pathway during physiological/steady-
state DNA replication.
In addition, immunofluorescence-coupled microscopy analysis
of ssDNA formation in S-phase cells (CldU positive) by BrdU
staining under native conditions further suggested that SPRTN-
defective cells do not form extensive ssDNA (Fig. 3d–f), a
platform for canonical and robust ATR-CHK1 activation. Similar
results were obtained with FA-treatment. HU or Camptothecin
(CPT) treatment was used as a positive control for DNA
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replication stress-induced ssDNA formation. However, when
SPRTN-depleted cells were exposed to a high dose of CPT or HU,
a striking increase in ssDNA (visualised as BrdU foci), generated
by 5′-3′ end resection of DSBs (Supplementary Fig. 3a, b), was
observed. This effect ruled out the possibility that this BrdU/
ssDNA assay was compromised in SPRTN-deficient cells owing
to reduced BrdU incorporation due to defective DNA replication
(Supplementary Fig. 1a–c). Altogether, these results suggest that
SPRTN plays a role in the activation of a physiological ATR-
CHK1 response during steady-state DNA synthesis but is
dispensable for CHK1 activation after DSB formation, when
substantial amounts of ssDNA is formed by 5′-3′ end resection.
SPRTN proteolysis releases CHK1 from replicating chromatin.
Given that SPRTN enables DNA replication by proteolysis of its
chromatin-bound substrates25,27 and that, in SPRTN-defective
cells, the ATR-CHK1 signalling cascade is not activated during
unperturbed conditions (Fig. 1), we considered potential inter-
actions between SPRTN and ATR-CHK1. First, we tested if
SPRTN forms a physical complex with ATR and CHK1 by pull-
down assays with SPRTN-wt from HEK293 cells under normal
conditions or during DNA replication stress induced by a low
dose of CPT (100 nM, Supplementary Fig. 4a)55. We verified that
components of DNA replication such as PCNA co-precipitate
with SPRTN along with CHK1. Interestingly, ATR could not be
detected in a SPRTN complex here. As CHK1, but not ATR, form
a physical complex with SPRTN and since the mechanism of
CHK1 release from chromatin to ensure proper activation of the
CHK1 signalling cascade is not known, we hypothesised that
SPRTN may directly regulate CHK1 and thus contribute to the
ATR-CHK1 signalling cascade during DNA replication.
To this end, we performed a series of in vitro and in vivo
experiments to show that CHK1 is a direct substrate of the SPRTN
protease. First, by cell fractionation we demonstrated that a small
but significant fraction of CHK1 is constantly bound to chromatin
(Fig. 4a, b). Additionally, CHK1 significantly hyper-accumulated
on replicative/S-phase chromatin isolated under stringent and
denaturing conditions in SPRTN-deficient cells during S-phase
progression (Fig. 4c, d), also indicating that a portion of CHK1 is
strongly attached to chromatin. Secondly, in vitro pull-down
experiments using purified SPRTN and CHK1 proteins confirmed
that the interaction between these two proteins is direct (Fig. 4e).
Thirdly, further co-immunoprecipitation experiments from
HEK293 cells expressing SPRTN-wt or the RJALS patient protease
defective variant SPRTN Y117C, confirmed that both form a
physical complex with CHK1, PCNA and MCM356, further
indicating that SPRTN and CHK1 are components of the DNA
replication machinery (Fig. 4f). Finally, using iPOND to directly
monitor SPRTN-dependent CHK1 dynamics on replicative
chromatin (Fig. 4g, h), we demonstrated that both CHK1 and
SPRTN are present at/around sites of DNA replication forks
(nascent DNA) and travel with the fork, as confirmed by their
absence from mature chromatin (after the thymidine chase)
(Fig. 4h). Importantly, inactivation of SPRTN led to a strong
accumulation of CHK1 on both nascent and mature chromatin
(Fig. 4i, compare lanes 2 and 3 with 4 and 5).
In light of these observations, we took advantage of iPOND to
assess if SPRTN proteolysis plays a role in CHK1 release/eviction
from sites of replicative chromatin. We analysed the abundance
of CHK1 by iPOND in SPRTN-knocked-down cells expressing an
empty vector (EV), SPRTN-wt or the SPRTN protease-deficient
variant E112A (Fig. 4j, k). Although both SPRTN variants were
equally expressed, SPRTN-wt strongly evicted CHK1 from
nascent (DNA replication sites) and mature chromatin, but
SPRTN-E112A did not (compare lanes 4, 5 to 6, 7 or 8, 9). A
similar effect was observed on total chromatin isolated by
biochemical fractionation (Supplementary Fig. 4b, c). Altogether,
these results support the model that the SPRTN-CHK1 complex
is involved with the DNA replication machinery and that SPRTN
proteolysis evicts CHK1 from replicating chromatin during DNA
synthesis.
SPRTN protease cleaves the C-terminal part of CHK1. As
SPRTN directly interacts with (Fig. 4e) and evicts CHK1 from
sites of DNA replication in a protease-dependent manner
(Fig. 4g–k), we investigated whether SPRTN proteolytically
cleaves CHK1. Purified Flag-CHK1 from HEK293 cells was
incubated with SPRTN-wt or a protease-deficient variant (E112A)
in vitro in the presence of dsDNA, an activator of SPRTN
metalloprotease activity (Fig. 5a). SPRTN-wt but not SPRTN-
E112A cleaved the C-terminal part of CHK1, generating at least
three N-terminal CHK1 fragments [Cleaved Products (CPs) 1, 2
and 3], as detected by anti-Flag antibody (Fig. 5a, b).
Similar N-terminal CHK1 fragments were observed on
endogenous CHK1 in S-phase but not in G0-phase of the cell
cycle in T24 urinary bladder carcinoma cell line or in HEK293
cells over-expressing SPRTN-wt (Fig. 5c, d). Importantly,
endogenous CHK1 cleaved fragments were completely SPRTN
protease dependent. Consistent results were observed with
ectopically expressed CHK1 in vivo (Supplementary Fig. 5a).
However, the formation of these cleavage products was reduced
in cells overexpressing the CHK1 variant S317A (Fig. 5e) or
treated with an ATR inhibitor (Supplementary Fig. 5b). These
results further support the premise that CHK1 is a substrate of
Fig. 2 Ectopic CHK1 overexpression rescues SPRTN-deficiency phenotypes. a Experimental strategy followed to assess the effect of different CHK1 variants
on DNA replication by DNA fiber assay (d: day, EV: empty vector). b Rescue of DNA replication defects in SPRTN-depleted HEK293 cells with ectopic
expression of CHK1-wt, but not with the phospho-deficient CHK1 variants. Graphs show quantification data from DNA fibers for replication fork velocity
(left panel; mean ± 25–75 percentile range (box) ± 10–90 percentile range (whiskers)), newly fired origins (centre panel; mean ± SEM) and stalled
replication forks (right panel; mean ± SEM); >100 DNA fibers were analysed per condition and experiment; n= 3 independent replicates, two-tailed
Student's t-test. c Overexpression of CHK1-wt diminishes the number of chromosomal aberrations caused by SPRTN knock-down visualised by metaphase
spreads from HEK293 cells. >30 cells were scored per condition per experiments; mean ± SEM; n= 3 individual experiments, two-tailed Student's t-test.
d Representative images of zebrafish embryos non-injected or injected with either a control or a previously characterised morpholino (MO) against SPRTN
at 9–10 h post fertilization (hpf). To assess CHK1 function, capped RNA encoding different mutants of GFP-tagged human CHK1 were co-injected with the
SPRTN MO. Upper row: live images. Middle row: pictures of γH2AX to show DNA damage. Lower row: Pictures of GFP to show expression of CHK1 protein
variants. e Representative images for normal, retarded and dead zebrafish embryos at 24 hpf. Scale bar= 500 µm. f–h Overexpression of CHK1-wt, but not
of the phospho-deficient CHK1 variants, rescues developmental defects and DNA damage induced by SPRTN depletion in zebrafish embryos. Percentage of
zebrafish embryos that show developmental retardation relative to living embryo are represented in (f) (mean ± SEM; >70 embryo were scored in n= 4
independent experiments, two-tailed Student's t-test), whereas data scoring normal, retarded and dead zebrafish embryos are represented in (h), Fisher’s
exact test. γH2AX, marker of DNA damage, is represented in (g) (mean ± SEM; at least 30 GFP-positive embryos were counted per condition; n= 2
replicates, two-tailed Student's t-test). Source data for (b, c, f–h) are provided as a Source Data file
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represent three experimental replicates. Source data for (a–c, e, f) are provided as a Source Data file
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SPRTN during S-phase of the cell cycle, and that upstream ATR-
phosphorylation assists CHK1 cleavage in vivo.
SPRTN is a DNA-dependent but amino-acid sequence
unspecific protease. Its known substrates histones are cleaved in
disordered protein regions in the vicinity of arginine, lysine and
serine residues25. The C-terminal part of CHK1 is also loosely
structured and serves as an inhibitory domain of the CHK1
kinase active centre located at Asp130 in the N-terminal part52,57.
To better understand how SPRTN cleaves CHK1, we created the
CHK1-7KA/3RA/8SA variant, where 7 lysines, 3 arginines and
8 serines were replaced with alanine in the predicted CP2 and
CP3 cleavage sites. These mutations increased local disorder
probability in mutated CHK1-7KA/3RA/8SA variant in the
vicinity of SPRTN cleavage sites (CP2 and 3) (Supplementary
b
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Fig. 5c, d). We observed strikingly stronger SPRTN-mediated
cleavage of CHK1-7KA/3RA/8SA variant in comparison to
CHK1-wt (Supplementary Fig. 5e), likely because these mutations
increased loosely structured protein regions and decreased the
overall protein stability of CHK1, making it a better SPRTN
substrate25.
SPRTN protease is a bona-fide CHK1 activator. To investigate if
the SPRTN-generated N-terminal CHK1 fragments are kinase
active, we first estimated the size of SPRTN-dependent CHK1
cleaved fragments by their molecular weight and designed con-
structs mimicking these CPs for expression in vertebrates (Fig. 5b
and Supplementary Fig. 5f). Interestingly, these CHK1 fragments
exhibited ~5–10-fold more potent kinase activity than CHK1 full-
length—even when the latter had been primed/activated by ATR
in the cells—and they were able to phosphorylate SPRTN or the
well-characterised CHK1 substrate Cdc25A in vitro (Supple-
mentary Figs. 5g–i and 6a). As expected, while the kinase activity
of full length CHK1 isolated from HEK293 cell treated with ATR
inhibitor was affected, the kinase activity of the N-terminal CHK1
fragments was refractory to ATR inhibitor (Supplementary
Fig. 6a).
Most notably, the N-terminal CHK1 products were fully
functional in vivo, as their ectopic expression was able to restore
DNA replication fork velocity and suppress new origin firing and
fork stalling in SPRTN-depleted cells (Fig. 5f). Importantly, the
recovery of DNA replication velocity with the N-terminal CHK1
product CP3 was sensitive to the CHK1 kinase inhibitor UCN-01
but resistant to the ATR kinase inhibitor VE-821 (Supplementary
Fig. 6b–d), and this rescue was completely dependent on the
kinase active centre Asp130 (Supplementary Fig. 6d). These
results further suggest that the N-terminal CHK1 fragments,
which mimic the cleaved CHK1 fragments generated by SPRTN
proteolysis, are kinase active and independent of ATR.
Similarly, expression of CHK1-CP3 corrected developmental
defects and suppressed DNA damage in SPRTN-depleted
zebrafish embryos to the same extent as full-length CHK1-wt
(Fig. 5g, compare with Fig. 2f, g).
To check if SPRTN proteolysis is a bona-fide CHK1 activator
in an ATR-independent setting, we designed an in vitro assay
with purified proteins from Escherichia coli expression system:
GST-CHK1, SPRTN-wt, SPRTN-E112 and Cdc25A (Fig. 5h). The
phosphorylation status of threonine 507 on Cdc25A was used as a
read-out for CHK1 activation.
Consistent with previous reports, the unmodified full-length
GST-CHK1 only phosphorylated Cdc25A with an extremely low
efficiency57. The complete inability of recombinant SPRTN to
phosphorylate Cdc25A by itself ruled out the possibility that
unspecific kinases from E. coli had been co-purified with SPRTN
(Fig. 5i, j and Supplementary Fig. 6e).
Remarkably, when CHK1 was cleaved by SPRTN in vitro
(Fig. 5h, i; top panel) its kinase activity increased by more than
20-fold (Fig. 5i—bottom panel, j). Catalytic proteolysis by SPRTN
was essential for this direct activation of CHK1 since the protease
inactive SPRTN-E112A mutant was unable to cleave CHK1
(Fig. 5i, upper gel) and stimulate its phosphorylating activity
(Fig. 5i, lower gel and Supplementary Fig. 6e).
Altogether, these results suggest (i) that the activation of CHK1
kinase activity is due to the SPRTN-dependent proteolytic
cleavage of its C-terminal part and (ii) that even a limited
proteolysis of CHK1 by SPRTN, generating a small fraction of
cleavage products as that observed in human cell lines or in a test
tube, is sufficient to trigger a potent CHK1 activation.
CHK1 stimulates recruitment of SPRTN to chromatin. Our
results so far indicate that SPRTN is needed for proper activation
of CHK1 during physiological DNA replication (Fig. 1). This
CHK1 activation occurs by both (i) SPRTN proteolysis-
dependent eviction of CHK1 from replicative chromatin
(Fig. 4g–k) and (ii) by simultaneous cleavage of the inhibitory/
regulatory C-terminal parts of CHK1 (Fig. 5a–e, h–j). Para-
doxically, ectopic expression of CHK1 restored various tested
phenotypes of SPRTN-deficiency both in human cells and zeb-
rafish embryos (Figs. 2 and 5f, g and Supplementary Fig. 6b–d).
As siRNA and MO-mediated SPRTN depletion is never 100%
efficient, we speculated that ectopic CHK1 expression stimulates,
by phosphorylation (Supplementary Fig. 5g), the remaining
SPRTN to process DPCs during DNA synthesis. Indeed, bio-
chemical analysis demonstrated that SPRTN-inactivated cells still
retain approximately 20–30% of SPRTN protein (Fig. 6a, b). To
investigate this possible cross-talk between SPRTN and CHK1, we
monitored SPRTN recruitment to chromatin after ectopic CHK1
expression (Fig. 6c, d). The amount of SPRTN on chromatin was
substantially increased after CHK1 overexpression, suggesting
that CHK1 induces SPRTN recruitment to chromatin. Impor-
tantly, the residual endogenous SPRTN in Δ-SPRTN cells (≈30%
of control cells; Fig. 6a, b) hyper-accumulated on chromatin after
CHK1 overexpression, almost to the same level as in untreated
wild-type cells (Fig. 6c, d). To further support these results, we
induced SPRTN-SSH expression in doxycycline-inducible
HEK293 cells and ectopically co-expressed CHK1-wt or the N-
terminal CHK1 cleaved fragments (CP1, 2 and 3). Ectopic
Fig. 5 SPRTN cleaves CHK1 and releases kinase-active CHK1 fragments. a Purified Flag-CHK1 was incubated with recombinant SPRTN-wt or SPRTN-E112A
(a protease-dead variant). Anti-Flag immunoblotting detected N-terminal CHK1 fragments released by the SPRTN proteolytic activity, referred to here as
CHK1 Cleavage Products (CPs) -1, -2 and -3 and indicated by blue arrows. Representative immunoblots from three replicates. b Graphical representation of
the three CPs released by SPRTN activity. The approximate size of these CPs was estimated from the immunoblots; CHK1 amino acids 1–338, 1–293 and
1–237, respectively. Red ticks represent the locations of Ser296, Ser317 and Ser345. Inh: autoinhibitory domain. c, d Endogenous CHK1 from T24 cells
synchronised in G0- or S-phase (c) or from HEK293 cells ectopically expressing SPRTN-wt or SPRTN-E112A (d) was immuno-purified under denaturing
conditions using a CHK1 antibody against an N-terminal CHK1 epitope. SE: short exposure, LE: long exposure. Quantification of the CHK1 fragments for (d).
Mean ± SEM; n= 3, two-tailed Student's t-test. e Lysates from HEK293 cells ectopically expressing Flag-CHK1-wt or Flag-CHK1-S317A were denatured and
CHK1 was then immuno-purified. Representative immunoblots from three replicates. f Ectopic expression of CHK1-CPs or CHK1-FL (full-length) in SPRTN-
inactivated HEK293 cells. Left: mean ± 25–75 percentile range (box) ± 10–90 percentile range (whiskers); centre and right: mean ± SEM. >100 DNA fibers
were analysed per condition and experiment; n= 3 experiments, two-tailed Student's t-test. g Ectopic expression of CHK1-CP3 in zebrafish embryos. Ref:
reference value for statistics. Mean ± SEM; n= 3, two-tailed Student's t-test. h Graphical description of experimental setting. In the first reaction, GST-
CHK1 was mixed with SPRTN-E112A or SPRTN-wt to generate CHK1 fragments (o/n, 37 °C); in the subsequent reaction, the product of the first reaction
was mixed with Cdc25A in a kinase buffer to induce its phosphorylation (30min, 37 °C). i Top panel: cleavage of CHK1 by SPRTN-wt after the first
reaction. Bottom panel: phosphorylation of Cdc25A by the products of the first reaction. j quantification of phospho-Cdc25A in (i). Experiment was
repeated 3 times with similar results. Source data for (a, c–g, i, j) are provided as a Source Data file
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expression of CHK1-wt stimulated SPRTN-SSH accumulation on
chromatin. Strikingly, ectopic expression of the N-terminal
CHK1 fragments additionally enhanced the SPRTN-SSH
recruitment to chromatin (Fig. 6e, f), and also phosphorylated
SPRTN much more than full length CHK1 (Supplementary
Fig. 5g, h). These results may explain why the ectopic expression
of CHK1-wt or its N-terminal fragments restores the phenotypes
arising from SPRTN-deficiency in human cell lines and zebrafish
embryos.
CHK1 phosphorylates the C-terminal regulatory part of
SPRTN. To identify CHK1 phosphorylation sites on SPRTN
in vivo, we performed mass spectrometry. SPRTN-E112A-SSH
was ectopically expressed in HEK293 cells co-transfected with
either CHK1-wt or the kinase-defective CHK1-S345A, and anti-
SSH precipitates were isolated under denaturing conditions
(Fig. 6g and Supplementary Fig. 7a). The SPRTN-E112A protease
dead mutant was used to avoid auto-cleavage activity25 (Fig. 5a,
lower panel). Mass spectrometry analysis identified three main
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CHK1 phosphorylation sites on SPRTN—serines 373, 374 and
383 (Fig. 6h, Supplementary Fig. 7b, c and Supplementary Data 1)
—located in the C terminal part of SPRTN. These sites corre-
spond to a consensus target motif of CHK1 (R/K-x-x-p(S/T))58.
To validate our results, we isolated SPRTN-wt-SSH or -S373A,
-S374A and -S383A variants from HEK293 cells treated with
DMSO or the CHK1 inhibitor UCN-01. SPRTN isolates were
analysed by Western blot using an antibody that recognises
CHK1 consensus sites (Fig. 6i, j). SPRTN-wt was phosphorylated
in control cells but this phosphorylation signal was strongly
decreased when cells were treated with UCN-01. Importantly,
SPRTN phosphorylation was strongly reduced (S373A or S383A)
or almost completely abolished (S374A) even when only one of
the three identified serines (S373, S374 and S383) was mutated.
This suggests that the C-terminal, regulatory part of SPRTN is
phosphorylated by CHK1 at these specific serines under steady
state conditions.
SPRTN-CHK1 cross-activation loop. To biologically validate the
biochemical evidence that CHK1 phosphorylates SPRTN and
thus regulates SPRTN’s function, we depleted SPRTN in HEK293
cells and tested the effects of ectopically-expressing variants of
SPRTN that either could or could not be phosphorylated by
CHK1. SPRTN-wt and SPRTN-phospho-mimetic variants S373E
and S383E restored DNA replication defects (Fig. 7a–c) and
promoted CHK1 release from chromatin (Fig. 7d). Conversely,
SPRTN phospho-defective variants S373A/374A and SPRTN-
S383A completely failed to restore these phenotypes in SPRTN-
depleted cells. Similar findings were observed in zebrafish
embryos (Fig. 7e, f). These data suggest that CHK1-mediated
phosphorylation of SPRTN is important for SPRTN’s function
in vivo.
To test our model in which a SPRTN protease-CHK1 kinase
cross-activation loop processes DPCs in front of the DNA
replication fork, we measured the progression of DNA replication
fork over FA-induced DPCs by DNA fiber assay (Fig. 8a).
Transient and low dose FA treatment strongly reduced DNA
replication fork velocity, but this could be significantly reversed
by the expression of either CHK1-wt or SPRTN-wt. This further
supports that both SPRTN and CHK1 prevent DPC-induced
DNA replication fork slowing and stalling.
Similarly, ectopic expression of CHK1-wt, but not of the kinase
deficient variant CHK1-S345A, reduced the levels of DPCs in Δ-
SPRTN HeLa cells to roughly the same level as in wild-type cells
(Fig. 8b, c). Altogether, these results support our model (Fig. 8d)
that a SPRTN-CHK1 cross-activation loop works during
physiological DNA replication to prevent DNA replication stress
and preserve genomic stability.
Discussion
A large body of evidence suggests that CHK1 is essential during
unperturbed DNA synthesis when the amount of ssDNA required
to activate the canonical ssDNA-ATR-CHK1 signalling cascade is
limited15,16,19,20,59. In recent years, a growing number of addi-
tional factors that activate ATR and CHK1 during replication-
associated DNA damage signalling have been described, such as
TopBP1, ETAA1 and Claspin21,22, as have DNA damage-
independent sources of ATR activation, like nuclear envelope
mechanical stress60. Despite this, the crucial question remains
unanswered: how CHK1 is released from chromatin and activated
during unperturbed DNA replication.
Our data and published literature12,13 suggest that ATR-
mediated phosphorylation is needed for efficient CHK1 cleavage,
chromatin release and activation of the ATR-CHK1 signalling
cascade and that SPRTN-dependent proteolysis is important to
sustain functional CHK1 activity during DNA replication.
SPRTN protease plays an important role in the activation of
CHK1 kinase during unperturbed DNA synthesis by removing
the C-terminal inhibitory domain of CHK1.
By using an in vitro reconstitution system of CHK1 activation
by SPRTN proteolysis, we additionally supported the proposed
model. This result also demonstrates that even a modest CHK1
cleavage by SPRTN—observed on both endogenous or over-
expressed CHK1 in vivo—is sufficient to strongly activate CHK1
kinase activity. As SPRTN cleaves CHK1 in a sequence-unspecific
manner in its loosely-structured C-terminal region, the exact size
of the N-terminal CHK1 fragments released is unimportant. This
is demonstrated by the observation that all three predicted N-
terminal CHK1 fragments are kinase active and able to restore all
tested phenotypes in SPRTN-deficient human cells. Even SPRTN-
deficiency phenotypes in Zebrafish embryos were rescued by
CHK1-CP3 fragment. Our results are further supported by pre-
vious work which demonstrates the inhibitory role of the C-
terminal part of CHK1 on CHK1 kinase activity57,61.
To ultimately prove the proposed model (Fig. 8d), a SPRTN
variant unable to interact with CHK1 in vivo would be needed.
Cells bearing SPRTN variants defective for CHK1 interaction are
expected to suffer from DNA replication stress as the steady-state
CHK1 activity would not be activated due to CHK1 chromatin
retention.
Our results also partially address how SPRTN is regulated
under physiological conditions by means of phosphorylation. The
Fig. 6 CHK1 phosphorylates SPRTN and regulates its recruitment to chromatin. a, b siRNA SPRTN-depleted HEK293 or haploinsufficient SPRTN HeLa cells
(ΔSPRTN) still contain a residual amount of SPRTN (10, 30%, respectively). Data are representative immunoblots (a) and quantification of SPRTN
normalised to vinculin (b). Mean ± SEM; n= 3, two-tailed Student's t-test. c, d CHK1 promotes SPRTN recruitment on chromatin. HeLa-wt or -ΔSPRTN
cells ectopically expressing CHK1-wt, or treated with formaldehyde (FA) as a positive control, were fractionated and endogenous SPRTN protein level was
assessed in the chromatin fraction. Residual SPRTN in ΔSPRTN cells were also recruited to chromatin. Representative immunoblots (c) and quantification
of SPRTN on chromatin (d). Mean ± SEM; n= 3, two-tailed Student's t-test. e, f Overexpression of CHK1-full length (FL) or N-terminal products (CP1, 2 or
3) promote SPRTN retention on chromatin. Doxycycline-inducible stable cells expressing SPRTN-wt-cSSH cells were fractionated and SPRTN was assessed
in chromatin fractions. Data are representative immunoblots (e) and quantification of HA (SPRTN) on chromatin (f). Mean ± SEM; n= 3, two-tailed
Student's t-test. g Schematics to identify the CHK1 phosphorylation sites on SPRTN by Mass-Spectrometry. h Diagram depicting human SPRTN with the
CHK1 phosphorylation sites on Ser 373, 374 and 383 identified in this study. SPRTN domain and motifs; DBS: DNA binding site; SHP box: p97 interacting
region; PIP box: PCNA interacting peptide; UBZ: ubiquitin binding domain. Sequence below (from SwissProt: Q9H040) shows the location of these sites
highlighted in red and amino acids surrounding the region. i, j The degree of phosphorylation at a CHK1 consensus target sequence is diminished in the
phospho-deficient SPRTN variants. Different SPRTN variants were expressed in HEK293 cells and purified under denaturing conditions. An antibody
recognizing the epitope Rxxp (S/T) (phospho-Ser/Thr preceded by Arg at position -3) was used to visualise CHK1 phosphorylated targets. The CHK1
inhibitor UCN-01 was used as a control. Data are representative immunoblots (i) and quantification of CHK1-mediated phosphorylation of SPRTN
normalised to total SPRTN protein level in denatured sample (j). Mean ± SEM; n= 3, two-tailed Student's t-test. Source data for (a–f, i, j) are provided as a
Source Data file
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regulation of SPRTN has a considerable interest given its pleio-
tropic protease activity. SPRTN is physically present at DNA
replication forks and the SPRTN gene is essential in metazoan
from early embryogenesis. It has been previously proposed that
ssDNA promotes SPRTN-dependent substrate cleavage while
dsDNA induces SPRTN auto-cleavage to negatively regulate
SPRTN activity26. However there are two arguments against this
model: (i) SPRTN is an essential enzyme for DPC repair during
DNA replication, yet DPCs prevent the helicase–polymerase
uncoupling and the ssDNA formation that would be required to
activate SPRTN, and (ii) SPRTN protease activity towards DNA-
binding substrates is also stimulated by dsDNA25,27, as
d
e
a
SPRTN MO
CT
RL
 M
O
+SPRTN-
N
on
-in
jec
ted
P 
<
 0
.0
00
1
P 
=
 
0.
10
82
P 
=
 
0.
80
78
P 
=
 
0.
00
01
P 
=
 
0.
83
31
R
e
f
SPRTN MO
CT
RL
 M
O
+SPRTN-
N
on
-in
jec
ted
R
et
ar
de
d 
em
br
yo
s 
(%
)
γH
2A
X 
(%
 po
sit
ive
)
20
0
40
60
80
100
20
0
40
60
80
100
P 
=
 
0.
00
05
P 
=
 
0.
00
86
P 
=
 
0.
68
00
P 
<
 0
.0
00
1
P 
=
 
0.
58
29
R
ef
N
ew
ly 
fir
ed
 o
rig
in
s 
(%
)
0
10
20
30
P 
<
 0
.0
00
1
P 
=
 
0.
00
02
P 
=
 
0.
16
22
P 
<
 0
.0
00
1
P 
=
 
0.
04
19
R
ef P
 =
 
0.
94
62
P 
<
 0
.0
00
1
Id
U 
tra
ct
 le
ng
th
 (μ
m
)
4
0
8
12
siSPRTN #1
+SPRTN-
P < 0.0001
P < 0.0001
P < 0.0001
P < 0.0001
CHK1
HA
H2B
siSPRTN #1siNS
+SPRTN-cSSH
Chromatin
50
75
20
kDa
1
0
2
3
4
CH
K1
 o
n 
ch
ro
m
at
in
(fo
ld 
ch
an
ge
)
siSPRTN #1
+SPRTN-
P = 0.0004
P = 0.0010
P = 0.0165
P = 0.0002
St
al
le
d 
fo
rk
s 
(%
)
5
0
10
15
20
P 
=
 
0.
00
02
P 
=
 
0.
00
05P
 =
 
0.
18
16
P 
<
 0
.0
00
1
P 
=
 
0.
38
53
R
e
f
P 
=
 
0.
27
77
P 
<
 0
.0
00
1
+SPRTN -
b c
f
siSPRTN #1
+SPRTN-
siSPRTN #1
siN
S
-
wt
-
S3
73
,S3
74
A
-
S3
73
,S3
74
,S3
83
A
-
S3
73
E,S
38
3E
-
S3
73
E
-
S3
83
E
-
S3
83
A siN
S
-
wt
-
S3
73
,S3
74
A
-
S3
73
,S3
74
,S3
83
A
-
S3
73
E,S
38
3E
-
S3
73
E
-
S3
83
E
-
S3
83
A
-
wtEV EV -S3
73
,S3
74
A
-
S3
73
,S3
74
,S3
83
A
-
S3
73
E,S
38
3E
-
S3
73
E
-
S3
83
E
-
S3
83
A
siN
S
-
wt
-
S3
73
,S3
74
A
-
S3
73
,S3
74
,S3
83
A
-
S3
73
E,S
38
3E
-
S3
73
E
-
S3
83
E
-
S3
83
A
siN
S
-
wt
-
S3
73
,S3
74
A
-
S3
73
,S3
74
,S3
83
A
-
S3
73
E,S
38
3E
-
S3
73
E
-
S3
83
E
-
S3
83
A
-
wt
-
S3
73
,S3
74
A
-
S3
73
E
-
S3
83
E
-
S3
83
A
-
wt
-
S3
73
,S3
74
A
-
S3
73
E
-
S3
73
E
-
S3
83
A
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11095-y ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:3142 | https://doi.org/10.1038/s41467-019-11095-y | www.nature.com/naturecommunications 13
Fig. 7 CHK1 targeted phosphorylation of SPRTN is essential for its biological function. a–c DNA replication analysis based on DNA fibers showing that
SPRTN phospho-defective mutants (S to A) are functionally impaired and unable to rescue DNA replication fork velocity (a), suppress new origin firing
(b) and decrease fork stalling (c) in SPRTN-depleted HEK293 cells, whereas SPRTN phospho-mimetic mutants (S to E) are functional and restore normal
DNA replication phenotype. Left: mean ± 25–75 percentile range (box) ± 10–90 percentile range (whiskers); right: mean ± SEM. >100 DNA fibers were
analysed per condition and experiment; n= 3 experiments, two-tailed Student's t-test. d SPRTN phospho-defective mutants failed to promote the eviction
of CHK1 from chromatin. Chromatin fractions from HEK293 cells were immunoblotted to show the effect of SPRTN variants on CHK1 release from
chromatin. Data are representative immunoblots (top) and quantification of CHK1 on chromatin fraction normalised to histone H2B (bottom). Mean ± SEM;
n= 3 experimental replicates, two-tailed Student's t-test. e, f SPRTN phospho-defective mutants were unable to rescue the zebrafish embryo
developmental retardation (e) and DNA damage (f, γH2AX positive signal) induced by SPRTN deficiency. SPRTN-depleted embryo cells (SPRTN MO) were
co-injected with plasmids for the expression of SPRTN variants. >70 embryos were scored per experiment. Mean ± SEM; n= 3 independent experiments,
two-tailed Student's t-test. Source data for (a–f) are provided as a Source Data file
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additionally demonstrated in this manuscript using CHK1 as an
in vitro substrate.
Our results suggest a model in which SPRTN protease activity
is regulated by CHK1 kinase activity during physiological DNA
replication. CHK1 constitutively phosphorylates SPRTN at the C-
terminally located serines S373, S374 and S383, which is essential
for DNA replication and embryonic development. Further
investigation should elucidate the phosphorylation dependant
regulation of SPRTN.
In summary, the DNA-replication coupled SPRTN-CHK1
cross-activation loop proposed here opens a new avenue in our
attempt to better understand genome instability associated with
DNA replication and places the protease SPRTN as a new
potential therapeutic target in cancer therapy based on targeting
DDR checkpoints62.
Methods
Key resources used in this study are listed and described in Supplementary Table 1.
Oligonucleotide sequences are listed in Supplementary Table 2.
Experimental models and cell culture. U2OS, HeLa and HEK293 human cells
were maintained in DMEM (Sigma-Aldrich) supplemented with 10% FBS (Gibco)
and 100 I.U./mL penicillin/0.1 mg/mL streptomycin at 37 °C in a humidified
incubator with 5% CO2, and tested for mycoplasma contamination. CRISPR partial
knockout Δ-SPRTN HeLa cells25 were maintained as above. Media for
doxycycline-inducible stable HEK293 Flp-In TRex SPRTN-wt or SPRTN-Y117A
cell lines25 was additionally supplemented with 15 μg/mL blasticidin/100 μg/mL
hygromycin. Wild-type zebrafish (Danio rerio EK and AB strains) were kept under
standardised conditions in a circulating water system on a 14 h light and 10 h dark
cycle. All procedures involving zebrafish embryos adhered to current European
regulations for the use of animals and were approved by the local authorities of
Ulm University.
Bacterial strains. Competent E. coli DH5alpha (Invitrogen) and E. coli Rosetta2
(Merck; Novagen), used for cloning/plasmid amplification or for protein expression,
respectively, were transformed with plasmid and grown in LB medium at 37 °C.
Subcloning and site-directed mutagenesis. The pCINeo/CMV-Flag-CHK1-wt
plasmid12 was used for expression in mammalian cells and to generate all CHK1
variants by site-directed mutagenesis. For the expression of CHK1 in Zebrafish,
CHK1 variants were subcloned into pCS2-GFP vector by PCR from previous
plasmids and EcoRI/XbaI insertion. Site-directed mutagenesis was performed by
plasmid PCR using specific mutagenic primers (sequences in Supplementary
Table 2) designed by the quick-change primer design software (Invitrogen) and
AccuPrime Pfx DNA-polymerase (Invitrogen). Mutations were then verified by
sequencing at Source BioScience, Oxford, UK. CHK1-7KA/3RA/8SA variant in
pCINeo/CMV-Flag plasmid was created by gene synthesis (Biomatik).
RNA interference and plasmid transfection. siRNA (sequences in Supplemen-
tary Information, Supplementary Table 2) transfections were performed using
Lipofectamine RNAiMax reagent (Invitrogen) according to manufacturer’s
instructions. Depletion was assayed 72 h post-transfection. Plasmid (Supplemen-
tary Information, Supplementary Table 1) transfections were performed using
either FuGene HD reagent (Promega) following the manufacturer’s instructions or
by PEI method. Protein expression was assayed 12–48 h post-transfection.
Denatured whole cell extracts. Cells were collected, washed three times in ice-cold
PBS and lysed in RIPA buffer (50mM Tris–HCl, pH 7.4, 150mM NaCl, 1% NP-40,
0.5% SDS, 0.1% SDS, 3 mM EDTA, 20mM N-ethylmaleimide (NEM), 1 mM DTT,
protease inhibitors [1 μg/mL Chymostatin, 1 μg/mL Aprotinin, 1 μg/mL Leupeptin,
1 mM PMSF] and phosphatase inhibitors [1mM Na3VO4×2H2O, 1mM Na4P2O7,
20mM NaF]). Extracts were then sonicated (20 cycles; 30/30 s on/off) in a Bioruptor
Plus sonicator (Diagenode).
Cell fractionation. Cells were incubated in 2× volumes of Buffer A (10 mM
HEPES, pH 7.4; 10 mM KCl; 1.5 mM MgCl2; 340 mM Sucrose; 10% Glycerol; 1
mM DTT; 5 mM EDTA; 20 mM NEM; protease and phosphatase inhibitors and
0.1% Triton-X100) on ice for 10 min. Sample was spun (350g, 4 min, 4 °C) and the
supernatant was collected as the cytosolic fraction. Nuclei were then washed once
with Buffer A without Triton-X100 and burst in 2× volumes of hypotonic Buffer B
(3 mM EDTA; 0.2 mM EGTA; 1 mM DTT; 10 mM NEM; protease and phospha-
tase inhibitors) on ice for 5 min. NaCl to 250 mM and NP-40 to 0.6% were added
and sample rotated for 10 min. After centrifugation at 2500g for 5 min, the
supernatant was collected as the nuclear soluble fraction. The pellet was washed
twice with Buffer B with 0.6% NP-40 and 250 mM (first wash) or 150 mM (second
wash) NaCl, and this was considered as the chromatin fraction. For chromatin
nuclease extracts, chromatin fraction was washed in Benzonase buffer (50 mM Tris
pH 7.5; 20 mM NaCl; 5 mM KCl; 3 mM MgCl2; protease and phosphatase inhi-
bitors) and incubated in same buffer at 4 °C with 100 u/mL Benzonase (Millipore).
Denaturing immunoprecipitation. Denatured extracts were first obtained by
lysing cells expressing tagged protein in denaturing buffer (50 mM Tris, pH 7.4;
137 mM NaCl; 5 mM KCl; 1% SDS; 1 mM DTT; 5 mM EDTA; 20 mM NEM;
protease and phosphatase inhibitors), heating at 95 °C for 5 min, shearing chro-
matin by 10–15 passes through a 22-gauge needle and sonicating—20 cycles; 30/30
s on/off—in a Bioruptor Plus sonicator (Diagenode), before been clarified by
centrifugation at 15,000g for 5 min. 10% of supernatant was retrieved for input.
Denatured extract was diluted 10-fold in IP buffer (50 mM Tris, pH 7.4; 150 mM
NaCl; 10 mM NEM; protease and phosphatase inhibitors) with 1% Triton X-100 to
quench SDS, and precleared with blank sepharose (IBA) and 2 U avidin for 1 h.
After incubation for 4 h to overnight with Strep-Tactin sepharose (IBA) or Anti-
Flag M2 affinity beads (Sigma-Aldrich), extract was washed twice with IP buffer
containing 500 mM NaCl and 1% Triton, and 3 times with IP buffer containing
137 mM NaCl and no detergents. Samples were finally eluted in 2× Laemmli buffer
for 10 min at 95 °C.
Protein co-immunoprecipitation. To isolate SPRTN-interacting proteins, non-
denaturing whole cell lysates were prepared from corresponding HEK293 Flp-In
TRex cell lines upon doxycycline induction of SPRTN-WT-cSSH (Strep-Strep-HA
tag). In addition, cell lysates were also prepared from HEK293 cells transiently
transfected with SPRTN-WT-cSSH and SPRTN-Y117-cSSH in order to compare the
capturing efficiency between SPRTN-WT and SPRTN-Y117C (patient mutation),
respectively. Cells were collected and lysed in non-denaturing lysis buffer [50mM
Tris pH 7.4; 150mM NaCl; 1% Triton; 1 mM EDTA; 10mM NEM; protease and
phosphatase inhibitors] with 2 U avidin (IBA Cat# 2-0204-015) at 4 °C. Following
centrifugation at 16,000g for 10min, the supernatant was kept at 4 °C and the pellet
was digested with Benzonase nuclease in Benzonase buffer (see above) at 37 °C for
1 h. Both supernatant and Benzonase digested fractions were pooled and 10% of this
pooled fraction was stored at −20 °C for later use as input. The rest of the lysate was
diluted 10 times in IP buffer [50mM Tris, pH 8; 150mM NaCl; 10mM NEM;
protease and phosphatase inhibitors] and precleared with blank sepharose (IBA
GmbH) for 1 h at 4 °C on a rotating wheel. Precleared samples were then incubated
with Strep-Tactin sepharose beads (IBA Cat# 2-1201-010) for 2 h at 4 °C, washed five
times in IP buffer containing 0.05% NP-40 and eluted in 2× Laemmli buffer
(62.5mM Tris–HCl, pH 6.8; 2% SDS, 10% Glycerol, 2.5% β-mercaptoethanol;
0.001% Bromophenol blue) for 10min at 95 °C.
Western blotting. Samples for WB were prepared following standard methods.
Briefly, protein concentration in cleared protein extracts was measured by Lowry
(Bio-Rad) and samples were denatured in Laemmli buffer (95 °C, 5 min). SDS-
PAGE was performed in TGS buffer. After transfer, membranes were blocked in
TBST buffer with 5% milk (RT, 1 h), washed with TBST and incubated (overnight,
4 °C) with primary antibody (Supplementary Information, Supplementary Table 1)
diluted 1:1000 in 2% BSA in TBST. Membranes were then washed four times in
TBST, incubated (RT, 1 h) with HRP-conjugated secondary antibody (Supple-
mentary Information, Supplementary Table 1) in TBST with 1% milk, and washed
4 times in TBST. Protein was then visualised using ECL substrates (Thermo Sci-
entific and Bio-Rad) in a ChemiDoc MP system (Bio-Rad) or with X-ray film.
Quantification of immunoblots was performed using ImageLab software (BioRad)
or ImageJ. Specific protein level values were calculated relative to the corre-
sponding loading control. Statistical significances of replicate measurements were
analysed in GraphPad Prism.
Isolation of proteins on nascent DNA: iPOND. To perform iPOND25, newly
synthesised DNA (~2 × 108 cells per condition) was labelled via incubation with
10 μM EdU for 10 min (in SPRTN-wt cells) or 15 min (in SPRTN depleted cells).
For mature chromatin, cells were chased with thymidine for further 5 min.
Chromatin fragmentation into 300–500 bp fragments was done in a Bioruptor Plus
sonicator (Diagenode) (70 cycles, 30/30 s on/off). After conjugation of biotin to
EdU by click chemistry63, proteins on EdU-labelled DNA were isolated with
streptavidin-coupled agarose beads.
DNA fiber assay. Asynchronous cells25,31 were labelled with 30 μM CldU for
30 min and then with 250 μM IdU for additional 30 min. For assay of genotoxic
stress, IdU was incubated in the presence of drugs. DNA replication was inhibited
with ice-cold PBS. Cells were lysed in 200 mM Tris–HCl pH 7.4, 50 mM EDTA and
0.5% SDS; DNA fibers were spread onto positively charged glass slides, fixed with
3:1 methanol: acetic acid (v/v), denatured with 2.5 N HCl, blocked with 2% BSA in
PBS containing 0.001% Tween-20, and stained for 1 h at 37 °C with anti-BrdU that
specifically recognize either CldU (clone BU1/75(ICR1)) or IdU (clone B44). After
incubation, slides were washed three times with PBS containing 0.05% Tween-20
(PBS-T) and briefly blocked again. Anti-rat Cy3 (Jackson Immuno Research) and
anti-mouse Alexa-Fluor 488 (Molecular Probes) were the respective secondary
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antibodies. Slides were washed 3 times with PBS-T, air-dried at RT and mounted
with ProLong Gold antifade reagent (ThermoFisher). Microscopy was performed
using a Leica DMRB microscope with a DFC360FX camera. Quantification of
CldU- and IdU-labelled DNA tract lengths was done with ImageJ software on at
least 100 fibers per condition in at least three independent experiments, converting
arbitrary units to microns based on the microscope scale. Resulting “Tract length”
values were represented in box graphs showing the mean (bar) with the 25–75
percentile range (box) and the 10–90 percentile range (whiskers) and statistically
analysed using GraphPad Prism. Analysis of newly fired origins and of stalled forks
were performed as above but on at least 400 fibers per condition tested, and data
was represented as plot the mean ± SEM of at least three independent experiments.
Metaphase spreads. HEK293 cells31 were treated with 100 ng/mL colcemid for
2 h, trypsinized, collected and incubated with 0.4% KCl at 37 °C for 15 min. Fol-
lowing the addition of fixative solution (3:1 methanol:acetic acid), cells were cen-
trifugated at 1000g for 10 min, resuspended in 5 mL fixative solution, incubated at
RT for 15 min, centrifuged, resuspended in 1 mL 100% acetic acid, incubated at RT
for 10 min, centrifuged, and finally resuspended in 5 mL of fixative solution.
Metaphase spreads were prepared by dropping the cell suspension from a height
onto pre-wetted slides. The slides were air dried, stained with DAPI and examined
by microscopy. Analysis were performed on at least 30 metaphases per sample.
Immunofluorescence microscopy. Cells grown on round coverslips were washed
once with ice-cold PBS, pre-extracted for 3 min with ice-cold pre-extraction buffer
(25 mM HEPES pH 7.5; 50 mM NaCl; 1 mM EDTA; 3 mM MgCl2; 300 mM
Sucrose; 0.5% Triton-X100) and fixed by adding methanol and 30 min incubation
at −20 °C. Fixed cells were then washed three times with PBS, blocked with 3%
BSA in PBS with 0.5% Tween-20 for 1 h at RT, incubated (90 min, RT) with the
primary antibody, washed three times, and incubated with the corresponding
secondary antibody (45 min, RT). Incubation with DAPI was done for 15 min at
RT. Finally, coverslips were mounted onto clean glass slides with mounting media.
Microscopy was performed using a Leica DMRB microscope with a DFC360FX
camera.
ssDNA foci. For the detection of single-stranded DNA (ssDNA) under non-
denaturing condition64, cells were seeded on coverslips, transfected with siRNA
and 24 h after, treated with 10 μM BrdU (Sigma-Aldrich) for further 48 h, and then
pulse-labelled with 100 μM CldU for 30 min before being treated with replication
interfering drugs. Cells were washed with PBS, pre-extracted, fixed and blocked as
above. ssDNA was marked with anti-BrdU (clone B44; 1:100 dilution) for 1 h, then
three washes with PBS, followed by secondary anti-mouse Alexa-Fluor 488 anti-
body (Molecular Probes, 1:1000 dilution) for 30 min and three washes. The pri-
mary and secondary antibody conjugates were then fixed with 4% formaldehyde in
PBS for 15 min followed by another wash. DNA was then denatured in 1.5 N HCl
for 30 min and washed with PBS. For the detection of replication foci after
denaturation, sample was incubated with anti-CldU antibody (clone BU1, 1:100
dilution) for 1 h, washed twice with PBS, then with high salt buffer (PBS with
200 mM NaCl, 0.2% Tween-20 and 0.2% NP-40) for 15 min and then with PBS
again, then incubated with anti-rat IgG Cy3 antibody (Jackson Immuno Research,
1:2000 dilution), and washed again. Finally, coverslips were mounted in mounting
medium supplemented with 2× DAPI. Images were taken with a Leica DMRB
microscope with a DFC360FX camera.
DNA protein crosslink isolation and detection. DPCs were isolated using a
modified Rapid Approach to DNA Adduct Recovery (RADAR) assay65,25. Briefly,
1–2 × 106 cells were lysed in 1 mL of buffer containing 6M guanidine thiocyanate
(GTC); 10 mM Tris–HCl, pH 6.8; 20 mM EDTA; 4% Triton-X100; 1% Sarkosyl
and 1% DTT. DNA was precipitated by adding 100% ethanol, washed three times
in wash buffer (20 mM Tris–HCl, pH 6.8; 150 mM NaCl and 50% ethanol). DNA
was then solubilized in 1 mL of 8 mM NaOH. The DNA concentration was
quantified by treating a small aliquot of DNA with proteinase K (Invitrogen) for
3 h at 50 °C, followed by detection with PicoGreen dye (Invitrogen) according to
manufacturer’s instructions. Equal dsDNA loading was confirmed by slot-blot
immunodetection with an anti-dsDNA antibody (Abcam). Total DPCs after
electrophoretic separation on polyacrylamide gels were visualised by silver staining
using the ProteoSilver Plus Silver Stain Kit (Sigma-Aldrich) and specific proteins
were detected by Western-blot.
SPRTN purification. Rosetta (DE3) E. coli carrying the pNIC-ZB-SPRTN-wt or
pNIC-ZB-SPRTN-E112A plasmids25 was resuspended in lysis buffer (100 mM
HEPES, pH 7.5; 500 mM NaCl; 10% glycerol; 10 mM imidazole; 1 mM Tris(2-
carboxyethyl) phosphine (TCEP); 0.1% dodecylmaltoside (DDM); 1 mM MgCl2
and protease inhibitor cocktail (Merck)) and sonicated. 1 U Benzonase nuclease
was added to lysates before cell debris was pelleted by centrifugation. Lysates were
applied to a Ni-sepharose IMAC gravity flow column, washed with two column
volumes of wash buffer (50 mM HEPES, pH 7.5; 500 mM NaCl; 10% glycerol;
45 mM imidazole; 1 mM TCEP), and eluted in elution buffer (wash buffer but with
300 mM imidazole). Elution fractions were applied directly to a 5 mL Hitrap SP
HP column (GE Healthcare), washed with wash buffer 2 (50 mM HEPES, pH 7.5;
500 mM NaCl; 1 mM TCEP) and eluted with elution buffer (wash buffer but with 1
M NaCl). The purification tag was cleaved by the addition of 1:20 mass ratio of
His-tagged TEV protease during overnight dialysis into buffer A (20 mM HEPES,
pH 7.5, 500 mM NaCl, 0.5 mM TCEP). Samples were concentrated by ultrafiltra-
tion using a 30 kDa molecular weight cut-off centrifugal concentrator and loaded
onto size exclusion chromatography using a HiLoad 16/60 Superdex 200 column
(GE Healthcare) at 1 mL/min in buffer A. Protein identities were verified by LC/
ESI-TOF mass spectrometry25 and protein concentrations were determined by
absorbance at 280 nm (Nanodrop) using the calculated molecular mass and
extinction coefficients.
In vitro cleavage of CHK1. Recombinant SPRTN wt or E112A mutant were
purified in house from E. coli. Flag-CHK1 variants, wt or 7KA/3RA/8SA, were
purified from ectopically expressing HEK cells in non-denaturing conditions by
immobilisation in Flag-M2 affinity agarose beads and several washes containing
0.5% Triton X-100 and 1M NaCl, and then eluted with a Flag peptide (Sigma-
Aldrich). Recombinant GST-CHK1 was purchased from SinoBiological. Cleavage
reaction was performed typically in 15 μL volume containing, 2 μg SPRTN, sub-
strate (Flag-CHK1 or 0.2–1 μg GST-CHK1) and a 100 bp dsDNA oligonucleotide
probe (Supplementary Table 2; 30:1 molar ratio SPRTN:dsDNA) in cleavage buffer
(25 mM Tris, pH 7.4; 150 mM NaCl) at 37 °C for 4 h—o/n. The reaction was used
straightaway for kinase assay or stopped by the addition of Laemmli buffer and
boiling.
In vitro CHK1 kinase assay. (A) Flag-CHK1 species (full length or mimicking
cleavage products) were obtained from 108 HEK cells previously transfected with
expressing vectors and purified as above. (B) Recombinant GST-CHK1 was from
commercial sources. For phosphorylation activity, purified Flag-CHK1 species were
incubated (2 h) with 2 μg SPRTN, or alternatively 20–80 ng GST-CHK1 (either
untreated or previously proteolysed by SPRTN) was incubated (30 min) with
200–500 ng cdc25A, at 37 °C in a kinase reaction buffer (10 mM HEPES, pH 7.4;
1 mM ATP; 10 mM MgCl2; 5 mM KCl; 25 mM β-glycerophosphate and phos-
phatase inhibitors) in a total volume of 25 μL. The reaction was stopped by the
addition of 5× Laemmli buffer and boiling.
Manipulation and analysis of Zebrafish embryos. Wild-type zebrafish (EK and
AB strains) were kept under standardised conditions in a circulating water system
(Tecniplast, Germany). Eggs were collected from natural matings. At the one to
two cell stage, fertilized eggs were microinjected with a SPRTN or control mor-
pholinos (sequences in Supplementary Information, Supplementary Table 2)31 and
with in vitro synthesised, capped RNAs encoding different CHK1 variants fused to
GFP, which were prepared from linearised plasmids using the mMessage mMa-
chine SP6 Kit (Ambion). Alternatively, capped RNA encoding SPRTN variants
were co-injected. Growth retardation was assessed at 9 h post fertilization (hpf;
90% epiboly stage under control conditions) using an upright brightfield M125
microscope equipped with a IC80 HD camera (both Leica). Immunofluorescence
stainings were essentially prepared using a rabbit-anti-γH2Ax antibody (Genetex,
1:200 dilution) and imaged at a M205FA microscope equipped with a DFC365FX
camera (both Leica)66.
Mass spectrometry. Purified SPRTN was isolated by denaturing IP using Strep-
Tactin beads (IBA), from 2.5 × 108 HEK293 cells ectopically coexpressing SPRTN-
E112A-SSH and either CHK1-WT or CHK1-S345A. SPRTN isolates were reduced
with 5 mM DTT (Sigma-Aldrich; room temperature, 1 h), alkylated with 20 mM
iodoacetamide (Sigma-Aldrich; room temperature, 1 h), and extracted using a
double methanol/chloroform precipitation. Protein precipitates were resuspended
in 6M urea (with sonication), and diluted in a buffer containing 25 mM Tris–HCl
(pH 8.5) and 1 mM EDTA until the urea concentration was <1M. Protein was
subsequently digested with rLysC (Promega) for overnight at 37 °C. Peptides were
then desalted using a SOLA HRP SPE cartridge (Thermo Scientific Cat# 60109-
001) and dried.
Dried tryptic peptides were reconstituted in 12 µL of LC-MS grade water
containing 2% acetonitrile and 0.1% trifluoroacetic acid. Samples were
subsequently analysed by nano-LC_MS/MS using a Dionex Ultimate 3000 UPLC
coupled to a QExactive instrument (Thermo Scientific, Bremen, Germany)67–69.
Peptides were online desalted on a PepMap C18 column (300 µm × 5 mm, 5 µm
particle size, Thermo Fisher) for 1 min at a flow rate of 20 μL/min and separated on
a directly coupled nEASY column (PepMap C18, 75 μm× 500 mm, 2 μm particle,
Thermo Fisher) using a multistep gradient starting with 3 min at 2% acetonitrile in
5% DMSO with 0.1% formic acid (buffer B), followed by 60 min linear gradient up
to 35% buffer B at 250 nL/min flow rate, 7 min linear gradient up to 99% buffer B
and maintained at 99% buffer B for 5 min at a flow rate of 250 nL/min before
reverting to 2% buffer B for 3 min prior to a last 4 min at 99% solvent B. Full MS
scans were acquired over the m/z range of 380–1800 at a resolution of 70,000 at
200m/z (AGC target of 3 × 106 ions). MS/MS data was acquired in a data-
dependent manner by selecting the 15 most abundant precursor ions for HCD
fragmentation (CE of 28) and on MS/MS resolution of 17,500.
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Mass spectrometry data analysis. LC-MS/MS data was analysed by PEAKS
(V7.5; Bioinformatics Solutions Inc., Waterloo, ON, Canada) using PEAKS data-
base and PTM function. Data was searched against Human UniProtSwissProt
database (downloaded on August 2016) enabling the decoy function whilst
selecting LysC as enzyme (two missed cleavages; none non-specific cleavage), HCD
as fragmentation source, mass tolerance of 10 ppm for precursor ions (MS data)
and 0.05 Da for peptide fragment ions (MS/MS data); carbamidomethylation (C) as
a fixed modification, and oxidation (M), deamidation (NQ) and phosphorylation
(STY) as variable modifications. PEAKS-PTM results were filtered using a 1% FDR
at peptide level. Extracted ion chromatogram (XIC) of peptides of interest was
performed using Xcalibur Qual Browser (Thermo Scientific) enabling Gaussian
peak smoothing at 3 points and a mass tolerance of precursor ion (MS1) of 4 ppm.
Peaks areas were automatically calculated by the software. Mass spectrometry data
analysis for phospho-sites detection performed by PEAKS software is contained in
Supplementary Data 1.
Statistics and reproducibility. Every experiment was reproduced at least three
times, with similar results, except for the experiments shown in Figs. 2g and 7e, f,
which were repeated twice. Unless otherwise stated, the statistical method used for
comparison between experimental groups was unpaired two-tailed Student’s t-test
carried out using GraphPad Prism. Statistical significance was expressed as a P
value, where P < 0.05 was considered a statistically significant difference. Source
Data contain all raw numbers used for statistical analysis.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The Mass Spectrometry raw data reported in this paper have been deposited in the
ProteomeXchange Consortium via the PRIDE70 partner repository with the dataset
identifier PXD006741. The source data underlying Figs. 1c–k, 2b, c, f–h, 3a–c, e, f, 4b–f,
h–k, 5a, c–g, i, j, 6a–f, i, j, 7a–f and 8a–c, and Supplementary Figs. S1d–h, S2a–b, S3b,
S4a–c, S5a, b, e–i, S6a–e and S7a are provided as a Source Data file. All other data
supporting the findings are available from the corresponding author upon reasonable
request.
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